Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
Treatment of a patient with recurrent osteosarcoma with personalized pp65/tumor mRNA RNA-LP under an individual patient expanded access protocol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 21, 2026
CompletedFirst Posted
Study publicly available on registry
May 1, 2026
CompletedMay 1, 2026
April 1, 2026
April 21, 2026
April 21, 2026
Conditions
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Eligibility Criteria
You may qualify if:
- Participated in clinical trial
- Received pp65 RNA-LPs alone and had pp65/tumor mRNA RNA-LP manufactured
- Progressive disease prior to treatment with pp65/tumor mRNA RNA-LP
You may not qualify if:
- Diagnosis of recurrent OSA is not histopathologically confirmed (i.e. pseudoprogression)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Florida Health
Gainesville, Florida, 32608, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 21, 2026
First Posted
May 1, 2026
Last Updated
May 1, 2026
Record last verified: 2026-04